All AbMole products are for research use only, cannot be used for human consumption.
HO-3867 is a selective STAT3 inhibitor. HO-3867 blocks the JAK/STAT3 pathway in human ovarian cancer cell lines. HO-3867/cisplatin combination treatment significantly inhibites cisplatin-resistant cell proliferation in a concentration-dependent manner. HO-3867 induces G(2)-M cell cycle arrest in A2780 cells. HO-3867 promotes apoptosis by caspase-8 and caspase-3 activation.
APMIS. 2015 Oct;837-46.
Leukemia inhibitory factor promotes tumor growth and metastasis in human osteosarcoma via activating STAT3.
HO-3867 purchased from AbMole
2015 May.
Study on IL-17(A) in Regulating Omentum Metastasis and Drug Resistance of Ovarian Cancer
HO-3867 purchased from AbMole
. figure 4..jpg) |
Source | APMIS (2015). Figure 4. HO-3867 (Abmole Bioscience, Shanghai, China) |
| Method | The cellular growth, colony formation, and invasion assay | |
| Cell Lines | 143B cells | |
| Concentrations | ||
| Incubation Time | 24 h | |
| Results | In 143B cells, the cellular growth, colony formation, and invasion enhanced by LIF were partially neutralized by HO-3867 (Fig. 4B–D, p = 0.04, 0.016 and 0.05, respectively). |
| Cell Experiment | |
|---|---|
| Cell lines | A2780 (A2780R), PA-1, SKOV3, OV4, and OVCAR3 cells; human ovarian surface epithelial cell |
| Preparation method | Determining cell viability by a colorimetric assay using MTT. In the mitochondria of living cells, yellow MTT undergoes a reductive conversion to formazan, producing a purple color. Cells, grown to ~80% confluence in 75-mm flasks, are trypsinized, counted, seeded in 96-well plates with an average population of 7,000 cells/well, incubated overnight, and then treated with HO-3867 for 24 h. All experiments are done using 8 replicates and repeated at least three times. |
| Concentrations | ~20 μM |
| Incubation time | 24 hours |
| Animal Experiment | |
|---|---|
| Animal models | Mice bearing ovarian cancer A2780 tumor xenografts |
| Formulation | |
| Dosages | ~100 ppm |
| Administration | p.o. |
| Molecular Weight | 464.55 |
| Formula | C28H30F2N2O2 |
| CAS Number | 1172133-28-6 |
| Solubility (25°C) | DMSO |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related STAT Products |
|---|
| NSC 74859 (S3I-201)
NSC 74859 (S3I-201) is a selective Stat3 inhibitor with an IC50 of 86 μM. NSC 74859 (S3I-201) is effective in hepatocellular cancers with disrupted TGF-beta signaling.*The compound is unstable in solutions, freshly prepared is recommended |
| Fludarabine
Fludarabine (NSC 118218) is a STAT1 activation inhibitor and a DNA synthesis inhibitor. Fludarabine inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase. Fludarabine markedly inhibited VSMC proliferation in cell culture. Fludarabine also induces significant reduction of STAT-1 phosphorylation, whereas it does not change JAK2 activation. Fludarabine exhibits antiproliferative activity (IC50 = 1.54 μM in RPMI cells) and triggers apoptosis through increasing Bax and decreasing Bid, XIAP and survivin expression. |
| Niclosamide
Niclosamide is an inhibitor of STAT3 with an IC50 value of 0.25 μM. |
| Nifuroxazide
Nifuroxazide is a cell-permeable and orally available nitrofuran-based antidiarrheal agent that effectively suppresses the activation of cellular STAT1/3/5 transcription activity with IC50 of 3 μM against IL-6-induced STAT3 activation in U3A cells. |
| Stattic
Stattic is the first nonpeptidic STAT3 inhibitor, potently inhibits STAT3 activation and nuclear translocation with IC50 of 5.1 μM, highly selectivity over STAT1. Stattic inhibits STAT3 phosphorylation (at Y705 and S727). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
